BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
Business Wire India Five-year results of Phase 3 SEQUOIA study demonstrate durable benefits of BRUKINSA in patients with CLL Two oral presentations showcase promising safety and efficacy data for BTK…